SCHEMBL15193866

SCHEMBL15193866

N#Cc1cnc(-c2cnc3ccc(F)cn23)nc1N[C@@H]1CCCNC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 6/20 0.54
FLT3 P36888 6/20 0.47
IRAK1 P51617 3/20 0.47
CDK7 P50613 2/20 0.47
CCNH P51946 2/20 0.47
LCK P06239 1/20 0.47
RET P07949 1/20 0.47
PDGFRB P09619 1/20 0.47
BLK P51451 1/20 0.47
SRPK1 Q96SB4 1/20 0.47
CHEK1 O14757 4/20 0.44
MAPKAPK2 P49137 1/20 0.44
NRAS P01111 4/20 0.42
CCNT1 O60563 1/20 0.41
CCNK O75909 1/20 0.41
CCNE1 P24864 1/20 0.41
CDK2 P24941 1/20 0.41
CDK9 P50750 1/20 0.41
CDK12 Q9NYV4 1/20 0.41
JAK2 O60674 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15193868 1.00 IRAK4 (0.54) IRAK4FLT3IRAK1CDK7CCNH
SCHEMBL1994861 0.88 FLT3 (0.51) IRAK4FLT3IRAK1CDK7CCNH
SCHEMBL1994864 0.88 FLT3 (0.51) IRAK4FLT3IRAK1CDK7CCNH
SCHEMBL12616166 0.86 IRAK4 (0.54) IRAK4FLT3IRAK1CDK7CCNH
SCHEMBL1996301 0.86 FLT3 (0.49) IRAK4FLT3IRAK1CDK7CCNH
SCHEMBL2051378 0.86 FLT3 (0.49) IRAK4FLT3IRAK1CDK7CCNH
SCHEMBL1995527 0.86 IRAK4 (0.54) IRAK4FLT3IRAK1CDK7CCNH
SCHEMBL2054237 0.85 FLT3 (0.49) IRAK4FLT3IRAK1CDK7CCNH
SCHEMBL2054238 0.85 FLT3 (0.49) IRAK4FLT3IRAK1CDK7CCNH
SCHEMBL15193129 0.84 NRAS (0.50) IRAK4FLT3IRAK1CDK7CCNH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 IRAK4 12/4885FLT3 21/4885IRAK1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.